Top Markets
#1 Nesa Nesa +873.71%
#2 MetaDAO MetaDAO +28.63%
#3 Prom Prom +16.34%
#4 Gigachad Gigachad +16.01%
#5 cat in a dogs world cat in a dogs world +12.72%
#6 dogwifhat dogwifhat +12.22%
#7 Tornado Cash Tornado Cash +10.73%
#8 Utya Utya +10.14%
#9 The Black Bull The Black Bull +9.62%
#10 TROLL TROLL +8.16%
Coin of the day
Nesa Nesa
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Celltrion, Inc. Celltrion, Inc.

Celltrion, Inc.

068270
Rang in Aktien #830
Celltrion, Inc., a South Korean biopharmaceutical company, specializes in the... Celltrion, Inc., a South Korean biopharmaceutical company, specializes in the development and manufacturing of protein-based therapies, including treatments for oncology. Its commercial portfolio features established products such as Remsima, Truxima, and Herzuma, alongside a range of generic pharmaceuticals and diagnostic kits for COVID-19. The company maintains an extensive pipeline of antibody biosimilars currently undergoing various stages of clinical evaluation. Late-stage (Phase 3) candidates include CT-P17, aimed at rheumatoid arthritis, psoriatic arthritis, and inflammatory bowel disease (IBD); CT-P16, targeting metastatic colorectal and breast cancers; CT-P43, for inflammatory conditions like psoriasis, Crohn's disease, and ulcerative colitis; CT-P42, addressing diabetic macular edema; and CT-P59, developed for COVID-19. In Phase 2, CT-P27 is being tested for pandemic and seasonal influenza. Earlier in development, Phase 1 assets comprise CT-P39 for asthma and urticaria, CT-P41 for osteoporosis and bone loss, and CT-G20 for cardiomyopathy. Additionally, Celltrion maintains a collaboration with Inhalon Biopharma, Inc. to advance IN-006, an inhaled formulation of regdanvimab intended for the treatment of COVID-19 patients. Established in 2002, the company operates primarily from its headquarters in Incheon, South Korea.
Aktienkurs
$131.80
Marktkapitalisierung
$30.23B
Veränderung (1 Tag)
-1.75%
Veränderung (1 Jahr)
10.37%
Land
KR
Handel Celltrion, Inc. (068270)

Kategorie

Healthcare
Kursverlauf für Celltrion, Inc. (068270)
Höchster Schlusskurs: $136.94 am 2026-08-01

Niedrigster Schlusskurs: $4.23 am 2005-07-01
Kursverlauf der Aktie von Celltrion, Inc. von 2005 bis 2026
Jährliche Kursentwicklung
Jahr Leistung
2026 (TTM) 7.65%
2025 4.60%
2024 -3.56%
2023 3.81%
2022 -20.29%
2021 -45.68%
2020 128.22%
2019 -24.07%
2018 8.47%
2017 118.41%
2016 24.48%
2015 96.93%
2014 -5.33%
2013 46.20%
2012 -19.43%
2011 8.13%
2010 134.41%
2009 101.37%
2008 89.98%
2007 -33.41%
2006 -27.08%
2005 0.00%
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Aktienkurs Veränderung 1J% Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $548.76 41.09%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $1.01K 49.43%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $122.80 -12.47%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $139.50 450.30%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $764.47 7.57%
CH